Agonism and Antagonism at the Insulin Receptor

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Knudsen, Louise ^a,c   Hansen, Bo Falck ^b   Jensen, Pia ^b   Pedersen, Thomas Åskov ^b   Vestergaard, Kirsten ^b   Schäffer, Lauge ^a   Blagoev, Blagoy ^c   Oleksiewicz, Martin B ^d   Kiselyov, Vladislav V ^a   de Meyts, Pierre ^a  

^a HAGEDORN RESEARCH INSTITUTE   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d Arsanis Biosciences   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; PROTEIN KINASE B; THYMIDINE;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHINESE HAMSTER; CONTROLLED STUDY; FEMALE; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; LIPOGENESIS; MITOGENICITY; MOUSE; MUSCLE CELL; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELLS, CULTURED; CHO CELLS; CRICETINAE; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MICE; MYOBLASTS; PEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84871658759     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051972     Document Type: Article

References (50)

1. Kasuga M, Karlsson FA, Kahn CR (1982) Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science 215, 185-187.
2. Petruzzelli LM, Ganguly S, Smith CJ, Cobb MH, Rubin CS, et al. (1982) Insulin activates a tyrosine-specific protein kinase in extracts of 3T3-L1 adipocytes and human placenta. Proc. Natl. Acad. Sci. U. S. A. 79, 6792-6796.
3. Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, et al. (1985) The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40, 747-758.
4. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, et al. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313, 756-761.
5. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, et al. (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5, 2503-2512.
6. Whittaker J, Okamoto AK, Thys R (1987) High-level expression of human insulin receptor cDNA in mouse NIH 3T3 cells. Proc. Natl. Acad. Sci. U. S. A. 84, 5237-5241.
7. Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373-398.
8. De Meyts P (1994) The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 37 Suppl 2, S135-S148.
9. De Meyts P, Roth J, Neville DM, Gavin JR, Lesniak MA (1973) Insulin interactions with its receptors: experimental evidence for negative cooperativity. Biochem. Biophys. Res. Commun. 55, 154-161.
10. Schäffer L (1994) A model for insulin binding to the insulin receptor. Eur. J. Biochem. 221, 1127-1132.
11. McKern NM, Lawrence MC, Streltsov VA, Lou MZ, Adams TE, et al. (2006) Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 443, 218-221.
12. Kiselyov VV, Versteyhe S, Gauguin L, De Meyts P (2009) Harmonic oscillator model of the insulin and IGF1 receptors' allosteric binding and activation. Mol. Sys. Biol 5, 243.
13. Knudsen L, De Meyts, P, Kiselyov VV (2011) Insight into the molecular basis for the kinetic differences between the two insulin receptor isoforms. Biochem. J. 440(3), 397-403.
14. Weiland M, Brandenburg C, Brandenburg D, Joost HG (1990) Antagonistic effects of a covalently dimerized insulin derivative on insulin receptors in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U. S. A. 87, 1154-1158.
15. Pillutla RC, Hsiao KC, Beasley JR, Brandt J, Ostergaard S, et al. (2002) Peptides identify the critical hotspots involved in the biological activation of the insulin receptor. J. Biol. Chem. 277, 22590-22594.
16. Schäffer L, Brissette RE, Spetzler JC, Pillutla RC, Ïstergaard S, et al. (2003) Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc. Natl. Acad. Sci. U. S. A. 100, 4435-4439.
17. Jensen M, Hansen B, De Meyts P, Schäffer L, Ursø B (2007) Activation of the insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses. J. Biol. Chem. 282, 35179-35186.
18. Schäffer L, Brand CL, Hansen BF, Ribel U, Shaw AC, et al. (2008) A novel high-affinity peptide antagonist to the insulin receptor. Biochem. Biophys. Res. Commun. 376, 380-383.
19. Bonnesen C, Nelander G-M, Hansen BF, Jensen P, Krabbe JS, et al. (2010) Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin. Cell Biol. Toxicol. 26, 293-307.
20. Listov-Saabye N, Jensen MB, Kiehr B, Hansen EW, Svendsen JE, et al. (2009) MCF-7 human mammary adenocarcinoma cells exhibit augmented responses to human insulin on a collagen IV surface. J. Appl. Toxicol. 29, 470-477.
21. Oleksiewicz MB, Bonnesen C, Hegelund AC, Lundby A, Holm GM, et al. (2011) Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells. J. Appl. Toxicol. 31, 329-341.
22. Blagoev B, Kratchmarova I, Nielsen MM, Fernandez MM, Voldby J, et al. (2002) Inhibition of Adipocyte Differentiation by Resistin-like Molecule α. J. Biol. Chem. 277, 42011-42016.
23. Hansen BF, Danielsen GM, Drejer K, Sørensen AR, Wiberg FC, et al. (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem. J. 315, 271-279.
24. Whitesell RR, Gliemann J (1979) Kinetic parameters of transport of 3-O-Methylglucose and glucose in adipocytes. J. Biol. Chem. 254, 5276-5283.
25. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85-96.
26. Baker JG, Hill SJ (2007) Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol. Sci. 28, 374-381.
27. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, et al. (1992) Rational design of potent antagonists to the human growth hormone receptor. Science 256, 1677-1680.
28. Ilondo MM, Damholt AB, Cunningham BA, Wells JA, De Meyts P, et al. (1994) Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. Endocrinology 134, 2397-2403.
29. De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF1 receptors: Implications for drug design. Nat. Rev. Drug Discov. 1, 769-783.
30. Levitzki A, Mishani E (2006) Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 75, 93-109.
31. Leahy DJ (2008) A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell 13, 291-293.
32. Tager H, Thomas N, Assoian R, Rubenstein A, Saekow M, et al. (1980) Semisynthesis and biological activity of porcine [LeuB24]insulin and [LeuB25]insulin. Proc. Natl. Acad. Sci. U. S. A. 77, 3181-3185.
33. Olefsky JM, Saekow M, Tager H, Rubenstein AH (1980) Characterization of a mutant human insulin species. J. Biol. Chem. 255, 6098-6105.
34. Kobayashi M, Ohgaku S, Iwasaki M, Maegawa H, Shigeta Y, et al. (1982) Characterization of [LeuB-24]- and [LeuB-25]-insulin analogues. Receptor binding and biological activity. Biochem. J. 206, 597-603.
35. Diaconescu C, Saunders D, Gattner HG, Brandenburg D (1982) [Leu(B24)]- and [Leu(B25)]insulins are not antagonists of lipogenesis in adipocytes. Hoppe-Seylers's Z. Physiol. Chem. 363, 187-192.
36. Keefer LM, Piron MA, De Meyts P, Gattner HG, Diaconescu C, et al. (1981) Impaired negative cooperativity of the semisynthetic analogues human [LeuB24]- and [LeuB25]-insulins. Biochem. Biophys. Res. Commun. 100, 1229-1236.
37. Figlewicz DP, Best JD, Tager HS, Taborsky GJ Jr (1983) LeuB24]insulin is an insulin agonist at the liver in vivo. Am. J. Physiol. 245, E483-E488.
38. De Meyts P, Van Obberghen E, Roth J, Brandenburg D, Wollmer A (1978) Mapping of the residues responsible for the negative cooperativity of the receptor-binding region of insulin. Nature 273, 504-509.
39. Soos MA, Siddle K, Baron MD, Heward JM, Luzio JP, et al. (1986) Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. Biochem. J. 235, 199-208.
40. Soos MA, Field CE, Lammers R, Ullrich A, Zhang B, et al. (1992) A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J. Biol. Chem. 267, 12955-12963.
41. Gu JL, Goldfine ID, Forsayeth JR, De Meyts P (1988) Reversal of insulin-induced negative cooperativity by monoclonal antibodies that stabilize the slowly dissociating ("Ksuper") state of the insulin receptor. Biochem. Biophys. Res. Commun. 150, 694-701.
42. Verspohl EJ, Maddux BA, Goldfine ID (1988) Insulin and insulin-like growth factor I regulate the same biological functions in HEP-G2 cells via their own specific receptors. J. Clin. Endocrinol. Metab. 67, 169-174.
43. Benyoucef S, Surinya KH, Hadaschik D, Siddle K (2007) Characterization of insulin/IGF hybrid receptors: Contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem. J., 403, 603-613.
44. Vikram A, Kushwaha S, Jena GB (2011) Relative influence of testosterone and insulin in the regulation of prostatic cell proliferation and growth. Steroids 76, 416-423.
45. Vikram A, Jena G (2010) S961, an insulin receptor antagonist causes hyperinsulinemia, insulin-resistance and depletion of energy stores in rats. Biochem. Biophys. Res. Commun. 398, 260-265.
46. Ward CW, Lawrence MC (2009) Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor. BioEssays 31, 422-434.
47. Whittaker J, Whittaker LJ, Roberts CT Jr, Phillips NB, Ismail-Beigi F, et al. (2012) α-Helical element at the hormone-binding surface of the insulin receptor functions as a signalling element to activate its tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A. 109, 11166-11171.
48. Menting JG, Ward CW, Margetts MB, Lawrence MC (2009) A thermodynamic study of ligand binding to the first three domains of the human insulin receptor: Relationship between the receptor α-chain c-terminal peptide and the site 1 insulin mimetic peptides. Biochemistry 48, 5492-5500.
49. Smith BJ, Huang K, Kong G, Chan SJ, Nakagawa S, et al. (2010) Structural resolution of a tandem hormone-binding element in the insulin receptor and its implications for design of peptide agonists. Proc. Natl. Acad. Sci. U.S.A. 107, 6771-6776.
50. Ward CW, Lawrence MC (2012) Similar but different: ligand-induced activation of the insulin and epidermal growth factor receptor families. Curr. Opin. Struct. Biol. 22, 360-366.